Torsdag 24 April | 20:45:30 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-11 07:00 Bokslutskommuniké 2025
2025-10-29 07:00 Kvartalsrapport 2025-Q3
2025-07-09 07:00 Kvartalsrapport 2025-Q2
2025-05-22 N/A X-dag ordinarie utdelning IRLAB A 0.00 SEK
2025-05-21 N/A Årsstämma
2025-05-07 07:00 Kvartalsrapport 2025-Q1
2025-02-12 - Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-07-10 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2024-05-22 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-07 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-06-21 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2023-06-20 - Årsstämma
2023-05-10 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2021-05-06 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-08 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2020-05-07 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-06 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-28 - Split IRLAB A 1:5
2019-04-26 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2019-04-25 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning IRLAB A 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-16 - Årsstämma
2017-05-16 - Kvartalsrapport 2017-Q1
2017-02-27 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
IRLAB Therapeutics är ett svenskt forsknings- och läkemedelsbolag. Forskningen utgår ifrån bolagets egna forskningsplattform och är specialiserad mot behandling av hjärnsjukdomar, vanligen benämnt neurodegenerativa sjukdomar. I nuvarande stund har bolaget läkemedelskandidater specialiserade mot bland annat Parkinsons sjukdom. Huvudkontoret ligger i Göteborg.
2023-01-06 07:00:00

Gothenburg, Sweden, January 6, 2022 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, today announced that the company will participate in the 6th Neuroscience Innovation Forum hosted by Sachs Associates. The event is held on Sunday, January 8, 2023, in San Francisco, US, in connection to the Annual J.P. Morgan Healthcare Conference.

Richard Godfrey, CEO at IRLAB, will participate in the panel discussion “New Approaches to Parkinson’s and Movement Disorders” together with panelists from Rune Labs, Inc., Ipsen, Alterity Therapeutics and The Michael J. Fox Foundation for Parkinson’s Research. The panel is co-chaired by Cheryl Zimberlin, Investment Director, M Ventures and Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc. A company presentation will also be held at the event.

The 6th Neuroscience Innovation Forum (also called 6th NIF) is an in-person event and is held Memorial Club, San Francisco on the 8th of January 2023, a day before the 41st Annual J.P. Morgan Healthcare Conference. The main program for the 6th Annual NIF features more than 10 hours of high-level keynotes and panel discussions covering the latest developments in global biopartnering and investment, with additional panels covering scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly, which includes neuropsychiatry, ophthalmology, neurotech, and digital therapeutics. The target audience includes buy and sell-side analysts from investment banks and funds, alongside partnering executives from pharma, biotech, and medtech companies. It is anticipated to have over 250 delegates and 30 company presentations by established and emerging companies with part of the audience participating virtually.

More information can be found on the event webpage at https://www.sachsforum.com/6nif-about.html.